The Oncoguard® Liver test is a simple, yet sophisticated blood test offering a streamlined approach to HCC testing that can be integrated into your clinical workflow where it fits best for you. It delivers easy-to-interpret, actionable information in a single assessment.
A simplified testing pathway for most patients
The Oncoguard® Liver test is designed to be used in the clinical care pathway for at-risk patients.
Patients at risk for HCC
Alcohol
Genetic hemochromatosis
Non-alcoholic fatty liver disease (NAFLD)
Stage 4 primary biliary cholangitis
Alpha-1-antitrypsin deficiency
Other causes of cirrhosis
HCC testing
Adapted from AASLD guideline1
Please note that the Oncoguard® Liver test is not currently recommended as part of the AASLD guideline.
The Oncoguard® Liver test is intended for the qualitative detection of biomarkers associated with HCC and is indicated as an aid in the detection of HCC for adults with liver cirrhosis and/or chronic hepatitis B (HBV) who are at risk for HCC.
![content-image-15](/-/media/project/oncoguard/oncoguardliver/images/content-image-15.jpg?rev=e23594060a3f47a4ac521e0efd7dbac7)
Applicability
The Oncoguard® Liver test was assessed in patients undergoing HCC testing with various disease etiologies. This included patients with cirrhosis due to HCV infection, HBV infection, and alcoholism, as well as non-cirrhotic HBV patients. The studies also included patients with disease etiologies that are on the rise, including non-alcoholic fatty liver disease (NAFLD). The test demonstrates strong performance across all disease etiologies, giving it broad applicability in clinical practice.
![Chris-Conroy-Photography-2429-small](/-/media/project/oncoguard/oncoguardliver/images/chris-conroy-photography-2429-small.jpg?h=1084&iar=0&w=750&rev=e416d5ad69284d75a48c7aac09ab1f6e&hash=FC70456AE99B559A798AFE693E3AEEAC)
Consistency
A blood-based biomarker test like the Oncoguard® Liver test introduces a level of clarity and consistency you may not see with ultrasound assessments. Ultrasound sensitivity is often variable based on operator, equipment, and the patient’s overall morphology.1,2 Blood-based assessment offers consistency without concerns about patient weight, operator or equipment variability.
Convenience
The Oncoguard® Liver test requires a simple blood collection, enabling HCC testing from a single location. The convenience of a blood-based test may minimize the logistical challenges often encountered with traditional imaging procedures, helping more patients follow through with their care.
![GettyImages-521848481-tuberemoved](/-/media/project/oncoguard/oncoguardliver/images/gettyimages-521848481-tuberemoved.jpg?h=653&iar=0&w=980&rev=9dc3663276a2453999121306cea48c37&hash=BA889F0E3426C9598A42F5BDE94AEC64)
![content-image-18](/-/media/project/oncoguard/oncoguardliver/images/content-image-18.jpg?h=1133&iar=0&w=800&rev=fc292042d1db4e9fa09d88f37e74ee04&hash=40CE4DC8BE2F9F4E92E506B0908FF08A)
Let us help you get started
Contact the Customer Care Center at 1-844-870-8870 or fill out a form to request a visit with a representative.
The Oncoguard® Liver solution. Exactly what’s needed today.
Learn how to order the Oncoguard® Liver solution and interpret results.
References: 1. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. 2. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169-177. 3. Samoylova ML, Mehta N, Roberts JP, et al. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transpl. 2018;24(9):1171-1177.